surpass 4 tirzepatide Lilly's achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial SURPASS-4: Tirzepatide slows kidney disease
Pay in 4 interest-free payments of $7.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1





























